Samsung BioLogics, headquartered in Incheon, South Korea, has entered into the first manufacturing contract for its Plant 3 facility. According to the company, the contract is valued at approximately $148 million, if the product is successful in clinical development and moves to commercial launch.
 
The Plant 3 facility was completed last November and has 180,000 liters total capacity and is expected to be cGMP operational by 4Q18.

TH Kim, chief executive officer of Samsung BioLogics, said, “We are excited to enter into this partnership with a fast growing company and very pleased to be chosen to provide a high quality life-saving product to their patients. As products from our Plant 1 (6 x 5,000L) and Plant 2 (10 x 15,000L) facilities mature, Plant 3 will be utilized to supply those with increasing demand to ensure that we continue to meet our client’s demand. We continue to discuss long term partnerships with multiple biopharmaceutical companies for Plant 3. As such, the utilization rate in Plant 3 may ramp up more quickly than anticipated.”